Immucell CORP /DE/ 10-Q quarterly reports

ImmuCell Corporation's Q2 2026 results show significant revenue and net income increases, driven by First Defense product sales and strategic operational adjustments.

ImmuCell Corporation reported a significant financial turnaround in Q3 2025, moving from a net loss to net income, driven by improved gross margins and reduced product development expenses, despite ongoing Re-Tain commercialization challenges.

ImmuCell Corporation reported a significant turnaround in its second quarter 2025 financial results, driven by robust First Defense product sales and improved gross margins, while navigating ongoing Re-Tain regulatory challenges.

ImmuCell Corporation announces a profitable first quarter in 2025, driven by increased sales of its First Defense product line and improved gross margins.

ImmuCell Corporation saw a significant increase in sales and a reduction in net losses for the third quarter of 2024, driven by strong demand for its First Defense product line.

ImmuCell Corporation saw a significant increase in product sales during the second quarter of 2024 compared to the same period last year, but the company still reported a net loss.

ImmuCell Corporation saw a significant increase in product sales during the first quarter of 2024, driven by increased production and pricing, while continuing to navigate challenges related to past contamination events and ongoing product development.